Skip to main content

Study Details

xIRB AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial)

This study will test an investigational drug called BAN2401 for the treatment of individuals with preclinical Alzheimer's Disease. Participation may last up to 4 years.

This study is composed of two research trials aimed at preventing Alzheimer's Disease (AD) dementia. One is called AHEAD-3 and the other is called AHEAD-45. You may qualify to join one of the AHEAD Study prevention trials because you're aged 55-80 years and have normal memory and thinking abilities.

General Inclusion Criteria:

  • Only individuals who have intermediate or elevated levels of amyloid in their brain will be able to participate in these studies. The screening process for the AHEAD Study will use a Positron Emission Tomography (PET) scan to measure the level of amyloid in your brain.
  • Must have a study partner that is willing to participate as a source of information and who spends a minimum average of 10 hours per week with the participant (e.g., family member, significant other, friend, or caregiver).
Grant, Ian MichaelGrant, Ian Michael
NCT04468659 STU00212910
More Info

Follow Mesulam Center on